VamsidharVelchetiMDFACP FCCP

Oncology • New York, NY

Hematologic Oncology, Thoracic Cancer

Director, Thoracic Oncology Program, New York University

Join to view full profile

Dr. Velcheti is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Velcheti's full profile

Already have an account?

Office
160 East 34th Street
8th Floor
New York, NY 10016
Phone+1 212-731-5662

Summary

Vamsidhar Velcheti, MD FACP FCCP is a medical oncologist with expertise in thoracic oncology and cancer immunotherapy. He is currently a Staff physician and Associate Director of Center for Immuno-Oncology Research at the Cleveland Clinic in Cleveland, OH. His current work focuses on novel immunotherapy strategies to treat lung cancer and biomarker discovery. He is interested in clinical trial design and incorporation of biomarker studies into early drug trials.

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Ochsner Clinic FoundationResidency, Internal Medicine, 2007 - 2010
ArMed Forces Medical College PuneClass of 2003

Certifications & Licensure

NY State Medical License 2018 - 2026
OH State Medical License 2013 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Career development Award American Society of Clinical Oncology, 2015
Scott Hamilton CARES initiative research award 2015
ASCO Merit Award American Society of Clinical Oncology, 2013
Outstanding researcher of the year Yale Cancer Center/Hematology Oncology Fellowship program, 2013
Young Investigator American Society of Clinical Oncology, 2012
The Edward D. Frohlich Award Ochsner Clinic Foundation, 2010
Resident Researcher of the year Internal Medicine Program, Ochsner Clinic Foundation, 2010
Travel Scholarship American Society of Hematology in San Francisco, CA, 2008
Certificate of Merit and Excellence in design Radiological Society of North America, 2005
College Blues Award, Student Scientific Society Armed Forces Medical College, 2002
Join now to see all

Clinical Trials

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors Start of enrollment: 2010 Oct 01
Completed
Phase 1
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2, Phase 3
Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung Start of enrollment: 2013 Apr 05
Completed
Phase 2
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Start of enrollment: 2014 May 01
Completed
Phase 1
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2014 Jan 22
Completed
Phase 2
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) Start of enrollment: 2014 Feb 21
Completed
Phase 1, Phase 2
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 16
Terminated
Phase 2
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy Start of enrollment: 2014 Nov 01
Terminated
Phase 2, Phase 3
MK-3475 as Maintenance Therapy in Extensive Stage SCLC Start of enrollment: 2015 Feb 01
Completed
Phase 2
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2015 Apr 15
Completed
Phase 1, Phase 2
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) Start of enrollment: 2015 Jul 21
Active, not recruiting
Phase 3
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2016 Jan 08
Completed
Phase 1, Phase 2
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab Start of enrollment: 2016 Jan 01
Completed
Phase 1
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors Start of enrollment: 2017 May 31
Active, not recruiting
Phase 1
Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Start of enrollment: 2017 Jun 07
Completed
Phase 2
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients Start of enrollment: 2017 Jan 01
Withdrawn
Phase 1, Phase 2
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial Start of enrollment: 2017 Jun 06
Active, not recruiting
Phase 2
Nivolumab Alone or in Combination With Decitabine/Tetrahydrouridine in Non-small Cell Lung Cancer Start of enrollment: 2016 Sep 01
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors Start of enrollment: 2016 Jul 01
Completed
Phase 1, Phase 2
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2016 Oct 01
Terminated
Phase 1
A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2016 Sep 23
Completed
Phase 2
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer Start of enrollment: 2017 Aug 14
Active, not recruiting
Phase 2
Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC Start of enrollment: 2017 May 19
Terminated
Phase 1
An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2017 Mar 29
Completed
Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Start of enrollment: 2017 Mar 07
Recruiting
Phase 1, Phase 2
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) Start of enrollment: 2017 May 02
Recruiting
Phase 1, Phase 2
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer Start of enrollment: 2019 Apr 05
Active, not recruiting
Phase 3
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors Start of enrollment: 2020 Aug 31
Terminated
Phase 1, Phase 2
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer Start of enrollment: 2022 Nov 09
Terminated
Phase 1
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2021 Feb 17
Active, not recruiting
Phase 2
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities Start of enrollment: 2020 Dec 16
Recruiting
Phase 1, Phase 2
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy Start of enrollment: 2020 Dec 08
Active, not recruiting
Phase 2, Phase 3
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer Start of enrollment: 2020 Oct 26
Active, not recruiting
Phase 3
Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC Start of enrollment: 2023 Jan 24
Recruiting
Phase 2
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC Start of enrollment: 2020 Oct 08
Recruiting
Phase 2
Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients Start of enrollment: 2023 Apr 01
Not yet recruiting
Not Applicable
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2022 Oct 05
Recruiting
Phase 1
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors Start of enrollment: 2023 Nov 09
Terminated
Phase 1, Phase 2
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2019 Oct 31
Recruiting
Phase 1, Phase 2
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) Start of enrollment: 2023 Dec 21
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

682 citations
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy J. Price, Gerald Steven Falchook
The New England Journal of Medicine. 2021-06-04
11 citations
A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors.
Mehdi Alilou, Mohammadhadi Khorrami, Prateek Prasanna, Kaustav Bera, Amit Gupta
Science Advances. 2022-11-25
68 citations
A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
Toyoaki Hida, Vamsidhar Velcheti, Karen L. Reckamp, Hiroshi Nokihara, Pallavi Sachdev
Lung Cancer. 2019-09-16

Books/Book Chapters

Oncologic Emergencies in The Washington Manual of Oncology.
Velcheti V and Govindan, RLippincott Williams & Wilkins, Philadelphia, PennsylvaniaEdition 2,
Lung Cancer in The Washington Sub-speciality Manual of hematology& Oncology.
Velcheti V and Subramanian, JLippincott Williams & Wilkins, Philadelphia, PennsylvaniaEdition 2,
Lung Cancer in Internal Medicine Just the facts.
Velcheti V and Govindan, RLippincott Williams & Wilkins, Philadelphia, PennsylvaniaEdition 2,
Complementary, Alternative, and Integrative Therapies in Cancer Care in Principles and Practice of Oncology.
Velcheti VEditors: Govindan, R.Lippincott Wilkins and Williams
Join now to see all

Abstracts/Posters

Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study
Vamsidhar Velcheti, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Retrospective EHR Study on Effectiveness of Eltrombopag in Cancer Treatment-Related Thrombocytopenia
Vamsidhar Velcheti, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Non-small cell lung cancer (NSCLC) in octogenarians.
Velcheti V., Viswanathan, A., Sainani, N., Grove, L., Suresh, R., Baggstrom, M.Q., and Govindan, R, Proc Am SocClinOnc, 2006; abst # 1855
Clinical utility of routinely adding positron emission tomography (PET) to computer tomography (CT) and endoscopic ultrasound (EUS) in the initial staging of esophagea...
Velcheti V, Viswanathan A, Badhey N, Gao F, Peifer K, Edmundowicz S, Early D, Govindan R, Azar R, American College of Chest Physicians 2006 annual meeting in Salt Lake City
Distinctive characteristics of non-small cell lung cancer in younger paitents: A national cancer database (NCDB) analysis of patients under 40 years old (1998-2003).
Velcheti V., Goodgame B., Morgensztern D., Gao F., Baggstrom M., Govindan R, Proc Am SocClinOnc, 2007;abst #18035
Barriers for accrual to clinical trials in adult patients (pts) with non-small cell lung cancer.
Baggstrom M, Velcheti V, Malik M, Gilstrap E, Skelton A, Lange K, Foersterling D, Govindan R, 12th World Conference on Lung Cancer, Seoul, Korea
Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: Washington University experience.
Subramanian J, Velcheti V, Goodgame B, Morgensztern D, Gao F, Baggstrom M, Govindan R, 12th World Conference on Lung Cancer, Seoul, Korea
Distinctive characteristics of extrapulmonary small cell carcinoma: A Surveillance Epidemiology and End Results (SEER) snalysis.
Subramanian J., Velcheti V, Goodgame B.W., Govindan R., Morgensztern D, Proc Am SocClinOnc, 2008; abst #22106
Preclinical evaluation of bafetinib for treatment of glioblastomamultiforme.
Velcheti V, Peterson B, Levitt D J, Li L, Rodwig F, Prakash O, J Clin Oncol (Meeting Abstracts) May 2010 vol. 28 no.15_suppl 2082
Join now to see all

Lectures

Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCL...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
Cytokines in Cancer Immunotherapy: Recent Updates
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Overcoming Resistance to Immune Checkpoint Blockade
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

WCLC 2021: Cracking the 'Undruggable' KRAS Problem in Lung CancerSeptember 2021
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Join now to see all

Press Mentions

Taking on Acquired Resistance in EGFR-Mutant NSCLCNovember 1st, 2024
SCLC: Bispecific Antibody Shows Phase 1 PromiseJune 4th, 2023
New AI-Based Biomarker May Help Predict Immunotherapy Response for Patients with NSCLCJanuary 11th, 2023
Join now to see all

Grant Support

Cleveland Clinic Research Program Committee Research AwardCleveland Clinic Lerner Research Institute2014–Present
Computerized Histologic Risk Predictor (CHiRP) for early stage Lung Cancers Objectives: To develop and validate a computerized histologic risk predictor (CHiRP) to identify which early stage NSCLC patients, following surgery, will receive additional benefit from adjuvant chemotherapyNational institute of health2018–2023
Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancerAmerican Society of Clinical Oncology2015–2018
Young Investigtator AwardAmerican Society of Clinical Oncology2012–2013

Committees

Member, Cancer Education Committee, American Society of Clinical Oncology 2015 - Present
Education Committee, American Society of Clinical Oncology 2015 - Present
Member, Protocol Review and Monitoring Committee, Case Comprehensive Cancer Center, Cleveland, Ohio 2014 - 2015
Member, Yale-New Haven Hospital-Graduate Medical Education Committee 2012 - 2013